Objective-To investigate the effect of rosuvastatin on platelet deposition under controlled shear rate conditions and to identify new platelet proteins involved in the interaction with the activating substrate. Methods and Results-Platelet-vessel wall interaction and thrombosis take place under dynamic conditions involving the interaction of the exposed damaged vascular wall with the circulating blood cells and proteins. Blood was perfused over type I collagen at different wall shear rates, and platelet deposition was measured by confocal microscopy. Perfused effluent blood was collected, platelets were sequentially extracted based on differential protein solubility, and proteins were separated by 2D gel electrophoresis. Blockade of 3-hydroxy-3-methylglutaryl-coenzyme A reductase significantly reduced platelet deposition and modulated the expression pattern of 18 proteins in the platelet subproteome. Among them, an increase in platelet surface 78-kDa glucose-regulated protein (GRP78), a stress-inducible multifunctional endoplasmic reticulum protein, was clearly apparent. Immunoprecipitation of platelet GRP78 revealed its interaction with tissue factor. Moreover, blockade of surface GRP78 resulted in a substantial increase in platelet deposition and tissue factor procoagulant activity and in a decrease in clotting time. Conclusion-These findings demonstrate that blockade of 3-hydroxy-3-methylglutaryl-coenzyme A reductase reduces platelet deposition and inhibits GRP78 translocation from the platelet surface after shear and collagen activation. For the first time to our knowledge, this study reports on the presence and functional role of GRP78 in platelets and indicates that GRP78 has additional functions beyond those of a molecular chaperone. Key Words: platelets Ⅲ thrombosis Ⅲ glucose-regulated protein 78 Ⅲ statins Ⅲ thrombosis Ⅲ tissue factor T he first response to vascular injury consists of platelet adhesion to the damaged vessel wall or to exposed tissue components and is mediated by flow-regulated interactions that have a key influence on subsequent thrombus growth, often culminating in life-threatening complications. 1 Clinical results strongly suggest that the beneficial effects of statins (3-hydroxy-3-methylglutaryl-coenzyme A [HMG-CoA] reductase inhibitors) may also be related to factors beyond lowering systemic lipid levels. 2,3 The effects of statins are mediated via blockade of mevalonate formation, which results in reduction of cholesterol synthesis. The inhibition of mevalonate formation also results in reduced levels of isoprenoid derivatives, which play important roles in the isoprenylation of small GTPases of the Rho/Rac/Cdc42 family. 4 -6 Isoprenylation facilitates activation and translocation of these proteins from the cytosol to the plasma membrane and thereby supports the function of these intracellular signaling pathways, which are necessary for many cellular processes in the cardiovascular system. 4, 7, 8 Indeed, statins inhibit cell proliferation, improve endothelial function, reduce inflammation, stabilize the atherosclerotic plaque, and enhance fibrinolysis. 3, 9 Although contradictory findings about the effect of different statins on platelet inhibition have been reported, there is evidence for their antithrombotic properties, 10,11 even in the venous side. 12 Therefore, our purpose in the present study was to evaluate the short-term effect of rosuvastatin, a newly available HMG-CoA reductase inhibitor that seems to have higher lipid-lowering efficacy than other statins on platelet function under flow conditions. A proteomic analysis was performed to identify new potential platelet proteins modulated by the inhibition of HMG-CoA reductase involved in platelet-vessel wall interactions. For the first time to our knowledge, we report on the presence of a 78-kDa glucose-regulated protein (GRP78) in the platelet surface and its changes by shear stress. Our results also indicate that rosuvastatin induces inhibition of flow-dependent platelet deposition and inhibits GRP78 translocation from the platelet surface, even after platelet activation.
T he first response to vascular injury consists of platelet adhesion to the damaged vessel wall or to exposed tissue components and is mediated by flow-regulated interactions that have a key influence on subsequent thrombus growth, often culminating in life-threatening complications. 1 Clinical results strongly suggest that the beneficial effects of statins (3-hydroxy-3-methylglutaryl-coenzyme A [HMG-CoA] reductase inhibitors) may also be related to factors beyond lowering systemic lipid levels. 2, 3 The effects of statins are mediated via blockade of mevalonate formation, which results in reduction of cholesterol synthesis. The inhibition of mevalonate formation also results in reduced levels of isoprenoid derivatives, which play important roles in the isoprenylation of small GTPases of the Rho/Rac/Cdc42 family. 4 -6 Isoprenylation facilitates activation and translocation of these proteins from the cytosol to the plasma membrane and thereby supports the function of these intracellular signaling pathways, which are necessary for many cellular processes in the cardiovascular system. 4, 7, 8 Indeed, statins inhibit cell proliferation, improve endothelial function, reduce inflammation, stabilize the atherosclerotic plaque, and enhance fibrinolysis. 3, 9 Although contradictory findings about the effect of different statins on platelet inhibition have been reported, there is evidence for their antithrombotic properties, 10, 11 even in the venous side. 12 Therefore, our purpose in the present study was to evaluate the short-term effect of rosuvastatin, a newly available HMG-CoA reductase inhibitor that seems to have higher lipid-lowering efficacy than other statins on platelet function under flow conditions. A proteomic analysis was performed to identify new potential platelet proteins modulated by the inhibition of HMG-CoA reductase involved in platelet-vessel wall interactions. For the first time to our knowledge, we report on the presence of a 78-kDa glucose-regulated protein (GRP78) in the platelet surface and its changes by shear stress. Our results also indicate that rosuvastatin induces inhibition of flow-dependent platelet deposition and inhibits GRP78 translocation from the platelet surface, even after platelet activation.
GRP78 may play a role in thrombosis, beyond its function as an endoplasmic reticulum (ER) chaperone.
Methods
Blood was perfused over type I collagen at different wall shear rates, and platelet deposition was measured by confocal microscopy. 13 Perfused effluent blood was collected, platelets were sequentially extracted based on differential protein solubility, and proteins were separated by 2D gel electrophoresis. Western blot and immunofluorescence analysis were performed to study GRP78 expression in platelets. In addition, flow cytometry, tissue factor (TF) procoagulant activity, immunoprecipitation, and thromboelastographic studies were performed. Data are given as meanϮSEM unless otherwise indicated. An expanded methods section is available in the Supplemental Material (available online at http://atvb.ahajournals.org).
Results

Effect of Rosuvastatin on Shear-Induced Platelet Deposition and Glycoprotein IIb-IIIa Activation
In vitro rosuvastatin treatment significantly reduced platelet deposition triggered by collagen in porcine blood at both low and high wall shear rates. At 250 s Ϫ1 , platelet deposition was significantly reduced by rosuvastatin (PϽ0.001) ( Figure 1A At 1500 s Ϫ1 , the surface covered by platelets significantly decreased from 8561Ϯ1283 m 2 per field in nontreated blood to 3763Ϯ880 m 2 per field in blood treated with rosuvastatin, 8 mol/L, as shown in Figure 1C , which means a 56% reduction on platelet deposition (PϽ0.005). Furthermore, rosuvastatin was able to significantly reduce platelet adhesion in conditions in which coagulation was fully prevented and in conditions in which coagulation was triggered, with similar reduction levels in both conditions (Supplemental Figure I ).
Flow cytometry analysis showed that rosuvastatin, 8 mol/L, significantly reduced the extent of activation of glycoprotein (GP) IIb-IIIa on ADP-induced platelet activation (PϽ0.05), as shown in Figure 1D .
Proteome Changes in Rosuvastatin-Treated Platelets
Differential proteomic analysis was used to identify changes induced by rosuvastatin in effluent sheared porcine platelets from flow experiments run at 1500 s Ϫ1 . Average gels were obtained from pooling at least 3 independent experiments. After a first screening using a broad pH range (from 3 to 10), most changes induced by rosuvastatin were localized in a pH ranging from 5 to 8, which led us to study the proteome in a pH ranging from 5 to 8. Proteomic analysis revealed that rosuvastatin, 8 mol/L, modulated the expression pattern of 10 spots in the cytosolic fraction and 8 spots in the membrane-enriched fraction (Supplemental Table I and Supplemental Figure II ).
Identification of GRP78 and Changes Induced by Rosuvastatin
Among the different proteins modulated by rosuvastatin treatment, we identified GRP78 as a series of 3 spots (region 3 of Supplemental Figure II (approximately 30%) and a reduction of the expression in the Tris-soluble fraction (approximately 25%) in the 3 spots identified as GRP78 (Figure 2A and B) .
To confirm the changes observed by 2D analysis, we performed Western blot analysis from 1D gels of protein extracts from platelets subjected to the different treatments. Western blot analysis demonstrated an increase of GRP78 in the urea-detergent-soluble fraction in rosuvastatin-sheared platelets compared with control sheared platelets (PϽ0.05), as shown in Figure 2C . To further elucidate the effect of rosuvastatin on GRP78, both resting and postperfusion sheared nonpermeabilized human platelets were analyzed by confocal microscopy with antibodies against GPIIIa (CD61) and GRP78. In resting platelets, significant amounts of GRP78 were detected in the platelet surface. In sheared platelets (effluent postperfusion platelets), membrane GRP78 was weaker than in resting platelets. In contrast, sheared platelets that had been preincubated with rosuvastatin showed levels of surface GRP78 similar to resting platelets (Figure 3) .
Effect of GRP78 Blockade on Platelet Deposition and Coagulation
To investigate the functional role of GRP78 in platelet adhesion, a further set of 3-minute perfusion experiments at 1500 s Ϫ1 with human heparinized blood was performed in the presence of 10 g/mL of anti-GRP78 or nonimmune goat IgG as control before rosuvastatin treatment. Blockade of GRP78 resulted in a substantial increase in platelet deposition (PϽ0.001) compared with control samples, as shown in Figure 4A . Blockade of GRP78 in rosuvastatin-treated platelets also resulted in a significant increase in platelet deposition.
Interestingly, GRP78 blockade also resulted in a shortened clotting time (91Ϯ6 seconds versus 81Ϯ6 seconds, control versus blockade of GRP78; PϽ0.05), analyzed by thromboelastometry with the EXTEM assay, which measures the contribution of the extrinsic pathway of coagulation to clot formation ( Figure 4B ). Accordingly, blockade of GRP78 significantly increased tissue factor (TF)-procoagulant activity (PCA) (PϽ0.05) in whole blood membrane extracts. Furthermore, as shown in Figure 4C , blockade of GRP78 significantly increased TF-PCA in platelet-rich plasma (PRP) but not in platelet-poor plasma (PPP).
GRP78/TF Interaction
TF interacted with GRP78, as observed by GRP78 immunoprecipitation. Both total platelet lysates and platelet membrane fractions of resting untreated platelets showed interaction with TF ( Figure 5A ). We did not detect the presence of GPVI, GPIb, GPIV, or GPIIIa on GRP78 immunoprecipitates.
GRP78-TF colocalization in human platelets was analyzed by immunofluorescence. We observed that GRP78 colocalized with TF in platelets that adhered to collagen and in effluent sheared platelets. The increase in platelet surface GRP78 induced by rosuvastatin colocalized with TF. Indeed, a double immunostaining of TF and GRP78 in effluent sheared platelets showed that in control platelets 13.2Ϯ3.0% of the area positively stained for TF colocalized with the area that stained positively for GRP78; in rosuvastatin-treated samples, 54.7Ϯ12.0% of the area stained positively for TF colocalized with GRP78 ( Figure 5B ) (PϽ0.05). Similarly, when analyzing platelets that adhered to collagen, in control samples, 23.9Ϯ3.7% of platelets positively stained for TF colocalized with GRP78; in rosuvastatin-treated samples (with total platelet deposition significantly reduced), this percentage increased up to 45.1Ϯ5.9% (PϽ0.01) (Figure 6 ). Therefore, rosuvastatin maintained high GRP78 expression in the platelet surface that colocalized with TF. 
Discussion
In the present study, we demonstrate that HMG-CoA reductase inhibition reduces platelet-collagen interaction by reducing platelet adhesion and thrombus height under flow conditions and maintains GRP78 on the platelet surface.
The postperfusion confocal analysis allowed the study of thrombus formation on a thrombogenic substrate, such as collagen, by measuring platelet deposition and thrombus height. Rosuvastatin was able to reduce platelet deposition at both venous and arterial wall shear rates. Because HMG-CoA reductase inhibitors have been shown to exert several cellular effects through reduction of isoprenoid derivatives, we aimed to identify novel target proteins modified by statin treatment on platelets. Blockade of HMG-CoA reductase modulated the expression pattern of 10 proteins in the cytosolic fraction and 8 proteins in the membrane-enriched fraction. Most of the identified proteins differentially modulated by rosuvastatin, such as heat shock protein 70 and vinculin, are already known to be involved in platelet adhesion and spreading. 14, 15 However, we report herein for the first time, to our knowledge, that platelets have GRP78 in both the membrane and the cytosol. GRP78 is translocated from the platelet membrane by shear forces, and rosuvastatin inhibits this translocation in shear-activated platelets.
GRP78 is a multifunctional ER protein that participates in many cellular processes, such as translocation of newly synthesized polypeptides across the ER membrane, facilitating the folding and assembly of proteins by preventing aggregation and regulating calcium homeostasis. 16 -19 Although GRP78 resides in the ER lumen, a number of studies demonstrate that GRP78 is also located on the cell surface. 20 -22 Indeed, 2 independent groups have detected that a fraction of GRP78 can exist as a transmembrane protein 23, 24 in Chinese hamster ovary, human leukemia, bladder carcinoma, and human embryonic kidney 293 T cells. These observations are in agreement with our findings. Indeed, we identified GRP78 both in cytosolic-and membrane/ cytoskeleton-enriched fractions, and confocal analysis revealed that GRP78 translocated in and out of the membrane, depending on the activation state. On the other hand, there is evidence that GRP78 can be released from intact cells and that it has also been detected in serum samples from healthy subjects. 25 In fact, we also identified GRP78 in plasma from effluent blood (data not shown), which means that platelet GRP78 could eventually be released.
GRP78 is preferentially expressed in advanced atherosclerotic lesions 26 and on the fibrous cap surface in apolipoprotein E-deficient mice. 27 A recent study 28 has shown that atheroprone, but not atheroprotective flow upregulated GRP78 in endothelial cells via a p38 mitogen-activated protein kinase and ␣2␤1-dependent mechanism, and that increased GRP78 correlated with activation of the unfolded protein response, providing a protective compensatory effect in response to ER stress. We observed by confocal microscopy analysis that GRP78 localization in platelets appeared to depend on stimulation by shear rate and collagen. Membrane GRP78 expression was higher in resting platelets than in effluent platelets, suggesting that, on the shear-induced activation surface, GRP78 could have been either partially released or translocated inside the platelet. Interestingly, rosuvastatin-treated platelets maintained surface GRP78 expression after exposure to shear, probably indicating inhibi- tion of shear-induced translocation of GRP78. This effect was also observed by 2D and Western blot because GRP78 expression was significantly increased in the urea-enriched fraction. The urea-enriched fraction not only contains the external membrane fraction but also the cytoskeleton fraction, which may account for the slightly different GRP78 patterns observed by 1D and 2D and confocal microscopy in sheared platelets.
It has recently been shown that statins activate the unfolded protein response and induce protective GRP78 expression in macrophages. 29 In line with these findings, we observed that in normocholesterolemic animals, treatment with rosuvastatin also increased platelet GRP78 (both cytoplasm and membrane fractions; data not shown), thus suggesting a possible effect on megakaryocytes that is transmitted to the platelets. Further research in this area seems warranted.
GRP78 provides dual functions in either the ER or the cell membrane, where it has multiple binding partners. Herein, we show that blockade of GRP78 in flow experiments markedly increased platelet deposition and TF-PCA and significantly reduced clotting time, supporting a protective role of surface GRP78. Rosuvastatin was able to partially inhibit the increase in platelet deposition induced by GRP78 blockade, indicating that it exerts additional protective functions in addition to translocating GRP78 to the membrane. In fact, we observed an additional inhibitory effect of rosuvastatin beyond GRP78 effects because we found that rosuvastatin decreased GPIIbIIIa activation in ADP-induced activated platelets.
Cell surface-associated GRP78 has been speculated to serve a protective role by inhibiting TF through direct binding to the endothelium overlying the plaque. 30, 31 Indeed, we observed a shortened clotting time and increased procoagulant activity in whole blood membrane extracts and in PRP samples when blocking GRP78. Intriguingly, GRP78 blockade did not increase TF-PCA in PPP samples. Moreover, we found that platelet GRP78 actively interacted with TF. Confocal analysis of adhered and effluent platelets showed a greater degree of colocalization of GRP78 and TF in rosuvastatin-treated platelets. Because we observed that rosuvastatin maintained high levels of GRP78 on the platelet surface, the inhibitory effect of rosuvastatin in platelet adhesion could be attributed to reduced TF activity as the result of direct binding of surface GRP78 to TF. The role of surface GRP78 on thrombus growth could be related to its ability to attenuate TF activity or might be attributed to additional unknown mechanisms directly involved in platelet activation, which will require future studies.
In summary, our data indicate that rosuvastatin inhibits platelet deposition under flow conditions and maintains platelet surface GRP78 in shear-activated platelets. Our results also show that GRP78 interacts with TF, blocking its procoagulant activity and that GRP78 blockade increases platelet deposition and reduces clotting time, suggesting a protective effect of GRP78 against thrombus formation.
